Significant reductions in the risk of mild
cognitive impairment (MCI)*, and the combination of MCI and dementia**,
have been shown for the first time through aggressive lowering of
systolic blood pressure in new research results from the
federally-funded SPRINT MIND Study reported at the Alzheimer's
Association International Conference (AAIC) 2018 in Chicago.
"This is the first randomized clinical trial to demonstrate a
reduction in new cases of MCI alone and the combined risk of MCI plus
all-cause dementia," said Jeff D. Williamson, MD, MHS, Professor of
Internal Medicine and Epidemiology and Chief, Section on Gerontology and
Geriatric Medicine at Wake Forest School of Medicine. Williamson
reported these results at AAIC 2018.
The results of this large-scale, long-term clinical trial provide
the strongest evidence to date about reducing risk of MCI and dementia
through the treatment of high blood pressure, which is one of the
leading causes of cardiovascular disease worldwide.
"This study shows more conclusively than ever before that there are
things you can do -- especially regarding cardiovascular disease risk
factors -- to reduce your risk of MCI and dementia," said Maria C.
Carrillo, PhD, Alzheimer's Association Chief Science Officer. "To reduce
new cases of MCI and dementia globally we must do everything we can --
as professionals and individuals -- to reduce blood pressure to the
levels indicated in this study, which we know is beneficial to
cardiovascular risk."
Carrillo pointed out that these results fit well with recent
population data showing reductions in new cases of dementia in developed
Western cultures. These lower rates of dementia may be occurring as
these societies have begun to improve control of cardiovascular disease
risk factors through medication management, reducing smoking, and
greater awareness of healthy lifestyle.
"The future of reducing MCI and dementia could be in treating the
whole person with a combination of drugs and modifiable risk factor
interventions -- as we do now in heart disease," Carrillo suggested.
"These new blood pressure findings raise our level of anticipation for
the U.S. POINTER Study, which includes managing cardiovascular disease
risk factors as part of the multi-component lifestyle intervention."
The Alzheimer's Association U.S. Study to Protect Brain Health
Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a
two-year clinical trial funded by the Alzheimer's Association to
evaluate whether lifestyle interventions can protect cognitive function
in older adults at increased risk for cognitive decline. The
interventions include physical exercise, nutritional counseling and
modification, cognitive and social stimulation, and improved
self-management of health status.
Intensive Blood Pressure Control Significantly Reduces New Cases of
MCI, and Combined Risk of MCI and Dementia: SPRINT MIND Study
At AAIC 2018, Williamson and colleagues reported preliminary results
related to risk of dementia and cognitive decline from the Systolic
Blood Pressure Intervention Trial (SPRINT). SPRINT is a randomized
clinical trial that compared two strategies for managing high blood
pressure (hypertension) in older adults: an intensive strategy with a
systolic blood pressure goal of less than 120 mm Hg versus a standard
care strategy targeting a systolic blood pressure goal of less than 140
mm Hg. Previously, SPRINT demonstrated that more intensive blood
pressure control reduced the risk for cardiovascular morbidity and
mortality (NEJM, 11-26-15). SPRINT helped inform the 2017 American Heart
Association and American College of Cardiology high blood pressure
clinical guidelines.
SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND)
examined whether treating to the lower blood pressure target reduces the
risk of developing dementia and/or MCI, and reduces the total volume of
white matter lesions in the brain as shown by magnetic resonance
imaging (MRI).
Study participants were 9,361 hypertensive older adults with
increased cardiovascular risk (based on the Framingham risk score) but
without diagnosed diabetes, dementia or prior stroke. Participant mean
age was 67.9 years (35.6% women) and 8,626 (92.1%) completed at least
one follow-up cognitive assessment. In SPRINT MIND, the primary outcome
was incident probable dementia. Secondary outcomes included MCI and a
composite outcome of MCI and/or probable dementia. Each outcome was
adjudicated by an expert panel blinded to who was in each treatment
group.
Recruitment for SPRINT began in October 2010. At one year, mean
systolic blood pressure was 121.4 mmHg in the intensive-treatment group
and 136.2 mmHg in the standard treatment group. Treatment was stopped in
August 2015 due to cardiovascular disease (CVD) benefit after a median
follow up of 3.26 years, but cognitive assessment continued until June
2018.
Intervention -- According to
NEJM, 11-26-15, "All major
classes of antihypertensive agents were included in the formulary and
were provided at no cost to the participants. SPRINT investigators could
also prescribe other antihypertensive medications (not provided by the
study). The protocol encouraged, but did not mandate, the use of drug
classes with the strongest evidence for reduction in cardiovascular
outcomes, including thiazide-type diuretics (encouraged as the
first-line agent), loop diuretics (for participants with advanced
chronic kidney disease), and beta-adrenergic blockers (for those with
coronary artery disease)."
"Participants were seen monthly for the first 3 months and every 3
months thereafter. Medications for participants in the
intensive-treatment group were adjusted on a monthly basis to target a
systolic blood pressure of less than 120 mm Hg. For participants in the
standard-treatment group, medications were adjusted to target a systolic
blood pressure of 135 to 139 mm Hg, and the dose was reduced if
systolic blood pressure was less than 130 mm Hg on a single visit or
less than 135 mm Hg on two consecutive visits. ... Lifestyle
modification was encouraged as part of the management strategy."
In SPRINT MIND, the researchers found a statistically significant 19
percent lower rate of new cases of MCI (p=0.01) in the intensive blood
pressure treatment group. The combined outcome of MCI plus probable
all-cause dementia was 15 percent lower (p=0.02) in the intensive versus
standard treatment group. There was a non-significant reduction in
probable dementia alone (HR=0.83, p=0.10). Adverse events -- According
to NEJM, 11-26-15, "Serious adverse events occurred in 1793 participants
in the intensive-treatment group (38.3%) and in 1736 participants in
the standard-treatment group (37.1%) (hazard ratio with intensive
treatment, 1.04; P=0.25). Serious adverse events of hypotension,
syncope, electrolyte abnormalities, and acute kidney injury or acute
renal failure, but not injurious falls or bradycardia, occurred more
frequently in the intensive-treatment group than in the
standard-treatment group. Orthostatic hypotension as assessed during a
clinic visit was significantly less common in the intensive-treatment
group. A total of 220 participants in the intensive-treatment group
(4.7%) and 118 participants in the standard-treatment group (2.5%) had
serious adverse events that were classified as possibly or definitely
related to the intervention (hazard ratio, 1.88; P<0 .001="" 75="" according="" adverse="" age="" among="" and="" assignment="" but="" by="" cohort.="" did="" differ="" differences="" events="" group="" in="" magnitude="" not="" number="" of="" older="" or="" overall="" p="" participants="" pattern="" saes="" similar="" the="" those="" to="" treatment="" were="" years="">
"These results support the need to maintain well-controlled blood
pressure, especially for persons over the age of 50," said Williamson.
"A particular strength of SPRINT-MIND is that 30 percent of the
participants were African American and 10 percent were Hispanic."
"This is something doctors and the majority of their
community-dwelling patients with elevated blood pressure should be doing
now to keep their hearts -- and brains -- healthier. These new results
for maintaining cognitive health provide another strong rationale for
starting and maintaining healthy lifestyle changes in mid-life,"
Williamson added.
SPRINT MIND MRI Results
In a related abstract reported at AAIC 2018, Ilya Nasrallah, MD,
PhD, of the University of Pennsylvania, Philadelphia, reported
preliminary results from 673 participants in SPRINT MIND who were
recruited for brain magnetic resonance imaging (MRI). Primary outcomes
included change in total white matter lesion (WML) volume and total
brain volume (TBV). Follow-up MRIs were obtained for 454 (67.4%)
participants at a median of 3.98 years post-randomization.
In this sub-study, WML volume increased in both treatment groups,
however the increase was significantly less in the intensive treatment
group. There was no significant difference in total brain volume change.
In the intensive treatment group, WML volume increased by 0.28 cm3
compared to 0.92 cm3 in the standard treatment group (mean
difference=0.64 cm3, p=0.004).
TBV decreased by 27.3 cm3 in the intensive treatment group versus
24.8 cm3 in the standard treatment group (mean difference=2.54 cm3,
p=0.16).
White matter lesions are frequently indicative of small vessel
disease and linked to higher risk of stroke, dementia and higher
mortality. While white matter lesions are thought to increase the risk
of vascular dementia, they also may be a risk factor for Alzheimer's
disease. People living with dementia may have Alzheimer's disease and
white matter lesions at the same time. Research has demonstrated that
when people have more than one type of disease-related brain changes,
the cognitive consequences are greater.
Genomic Analysis of Phase 2a Alzheimer's Study with ANAVEX®2-73 May
Enable a Precision Medicine Approach "Precision medicine involves giving
the right therapy to the right patient at the right time, customized to
his or her specific biological makeup," says Professor Harald Hampel,
MD, PhD, MA, MSc, AXA Research Fund & Sorbonne University Excellence
Chair, Department of Neurology, Sorbonne University, Paris.
Precision medicine emphasizes the customization and
individualization of healthcare, with treatments and practices tailored
to the specific patient's situation and needs, often taking into account
genes, environment, and lifestyle. Sometimes called personalized
medicine, it is a common approach in cancer and respiratory diseases.
At AAIC 2018, Hampel and colleagues reported results of an
innovative attempt to move a step closer to precision medicine in
Alzheimer's therapy trials. Anavex Life Sciences (AVXL) conducted a
57-week Phase 2a study with ANAVEX®2-73, a selective sigma-1 receptor
agonist, in 32 people with mild to moderate Alzheimer's disease and
analyzed the entire genome DNA and RNA of all study participants,
resulting in the analysis of 33,311 genes and 860 pathways.
The company identified several genetic variants that impacted
response to the drug, including SIGMAR1, which is ANAVEX®2-73's target,
and COMT, a gene involved in memory function. They found further that
excluding people with these variants (~20% of the study group) --
leaving about 80% of the population -- resulted in improved scores on
gold standard tests of cognition (MMSE) and activities of daily living
(ADCS-ADL) (p<0 .05="" p="">
Including participants with milder disease (baseline MMSE?20) and
excluding those with a SIGMAR1 variant resulted in improvement of 1.7
MMSE and 3.9 ADCS-ADL at week 57. The additional exclusion of the COMT
variant resulted in a score improvement of 2.0 MMSE and 4.9 ADCS-ADL at
week 57.
"This study represents an exciting step forward, away from the
'magic bullet, one-size-fits-all' drug development in Alzheimer's,
following the targeted therapy successes in the field of oncology,"
Hampel said. "Our vision is that a precision medicine approach will
allow us to more precisely treat and prevent key features of the cause
and progression of Alzheimer's. We are intrigued that several studies
with this novel approach are now planned or underway."
According to the company, these patient selection markers will be implemented in an upcoming Phase 2b/3 study of ANAVEX®2-73.
###
The Alzheimer's Association International Conference® (AAIC®)
The Alzheimer's Association International Conference (AAIC) is
the world's largest gathering of researchers from around the world
focused on Alzheimer's and other dementias. As a part of the Alzheimer's
Association's research program, AAIC serves as a catalyst for
generating new knowledge about dementia and fostering a vital, collegial
research community.
AAIC 2018 home page:
alz.org/aaic
AAIC 2018 newsroom:
alz.org/aaic/press
About the Alzheimer's Association®
The Alzheimer's Association is the leading voluntary health
organization in Alzheimer's care, support and research. Our mission is
to eliminate Alzheimer's disease through the advancement of research, to
provide and enhance care and support for all affected, and to reduce
the risk of dementia through the promotion of brain health. Our vision
is a world without Alzheimer's. Visit
alz.org or call 800.272.3900.
0>0>